Discover innovative solutions and insights from leading pharmaceutical and life sciences companies driving advances in drug development, biotechnology, healthcare, and scientific innovation.
Decentralised clinical trials promise to transform drug development and pharma strategy. The evidence tells a complex story. Here is what’s working and what still needs to be fixed.
Ethical obligations in decentralised clinical trials extend beyond consent and privacy. Sponsors must protect safety, scientific validity, equity, and oversight.
Select the Right Data Collection Method for Real-World Evidence
Choosing the wrong RWE data source undermines your regulatory strategy. This framework helps pharma leaders select the right real-world data collection method based on your programme’s research question.
Cell Therapy for Solid Tumours: Current Challenges and New Advances
Cell therapy for solid tumours faces unique biological barriers. This analysis unpacks the engineering strategies pharma leaders must understand for R&D success in 2026.
Why Gynaecological Cancers Are Some of Pharma’s Most Important Challenges
Gynaecological cancers remain a major pharma challenge. Explore how disease burden, access, tumour biology, and precision medicine are shaping oncology R&D.
Can Deep Learning Survive the Precision Medicine Paradox?
As precision medicine narrows patient cohorts to rare‑disease scales, deep learning models face a paradox of data scarcity and overfitting that threatens the future of clinical AI.